Three year's after its initial rejection, the FDA last week approved...

...Novartis' biosimilar to Amgen's Neulasta, which is manufactured by the company's Sandoz unit. For the treatment of neutropenia, Neulasta is covered under both the medical and pharmacy benefit for 44% of covered lives. In the pharmacy benefit, Neulasta holds preferred status for 10% of covered lives, growing to 37% with prior authorization and/or step therapy. Neulasta also faces biosimilar competition from Mylan and Coherus BioSciences.

SOURCE: MMIT Analytics, as of 11/6/19